239 results on '"von Nussbaum, Franz"'
Search Results
2. The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models
3. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction
4. European Medicinal Chemistry Leaders in Industry (EMCL) – On the Status and Future of Medicinal Chemistry Research in Europe**
5. BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity
6. Suppl. Figure 1 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
7. Supplementary Figures from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
8. Supplementary Methods from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
9. Suppl. Figure 2 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
10. Suppl. Figure 4 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
11. Supplementary Materials and Methods; Supplementary Tables 1-6; and Supplementary Figure Legends from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
12. Supplementary Tables from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
13. Suppl. Figure 3 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
14. Data from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
15. Supplementary Table S1 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
16. Figure S2 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
17. Supplementary Figure Legends and Methods from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
18. Neutrophil elastase inhibitors for the treatment of (cardio)pulmonary diseases: Into clinical testing with pre-adaptive pharmacophores
19. Frontiers in Medicinal Chemistry 2022 Goes Virtual
20. BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling‐dependent tumor growth in mouse models
21. Front Cover: Industrial Organic Synthesis in Life Sciences – Today and Tomorrow (Eur. J. Org. Chem. 17/2022)
22. Discovery and Characterization of the Potent and Highly Selective 1,7-Naphthyridine-Based Inhibitors BAY-091 and BAY-297 of the Kinase PIP4K2A
23. Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer
24. Abstract 1470: Preclinical activity of the first reversible, potent and selective inhibitor of EGFR exon 20 insertions
25. Industrial Organic Synthesis in Life Sciences – Today and Tomorrow.
26. Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models
27. Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase
28. The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
29. Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor
30. β-Amino Acids in Natural Products
31. Alkaloids from marine organisms. Part 8: Isolation of bisdemethylaaptamine and bisdemethylaaptamine-9- O-sulfate from an Indonesian Aaptos sp. marine sponge
32. Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
33. Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2-d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5
34. Alkaloids from marine organisms. Part 7: Synthesis of bisdemethylaaptamine and bisdemethyloxyaaptamine—a biomimetic approach to the aaptamines?
35. Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer
36. Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor
37. Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2‑d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5.
38. BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling‐dependent tumor growth in mouse models
39. Abstract 341: Preclinical mode of action and anti-tumor efficacy of the selective MKNK1 inhibitor BAY 1143269 in NSCLC models
40. Abstract 3022: BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML)
41. Abstract 2725: Probing mitotic functions of BUB1 kinase using the small molecule inhibitors BAY-320 and BAY-524
42. Abstract 4851: Second generation 2,3-dihydroimidazo[1,2-c]quinazoline PI3K inhibitors: development of BAY 1082439, a novel balanced PI3Ká / PI3Kâ inhibitor
43. Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
44. Probing the catalytic functions of Bub1 kinase using the small molecule inhibitors BAY-320 and BAY-524
45. Author response: Probing the catalytic functions of Bub1 kinase using the small molecule inhibitors BAY-320 and BAY-524
46. BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients
47. Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2-d]pyrimidine Based in VitroProbe BAY-885for the Kinase ERK5
48. ChemInform Abstract: Neutrophil Elastase Inhibitors for the Treatment of (Cardio)pulmonary Diseases: Into Clinical Testing with Pre‐Adaptive Pharmacophores
49. Potent and Selective Human Neutrophil Elastase Inhibitors with Novel Equatorial Ring Topology: in vivo Efficacy of the Polar Pyrimidopyridazine BAY‐8040 in a Pulmonary Arterial Hypertension Rat Model
50. Abstract 2604: Preclinical anti-tumor efficacy and mode of action of a novel, orally available, selective MKNK1 inhibitor [BAY 1143269]
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.